INBX stock forecast, quote, news & analysis
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms... Show more
Why Inhibrx Biosciences (INBX) Stock Is Down -27% in the Last 30 Days
Key Takeaways
- INBX shares have fallen roughly 27% over the last 30 days, sliding from about $101.71 to near $73.90 and moving into a pronounced short-term downtrend.
- The decline marks a sharp reversal from a late-August rally that briefly carried the stock above $126.
- A lukewarm market response to INBRX-106 head-and-neck squamous cell carcinoma (HNSCC) data in early September served as a key inflection point, followed by sustained selling pressure.
- As a clinical-stage biotech with no approved products, Inhibrx remains highly sensitive to clinical data readouts and shifting biotech risk appetite.
- Inhibrx's pipeline is led by two oncology candidates, ozekibart (INBRX-109) and INBRX-106, built on its proprietary modular protein-engineering platform.
- Investors can explore additional detail on Inhibrx's Price Targets, Earnings, and Forecast on dedicated pages.
- Traders interested in systematic strategies can explore Trending AI Robots to see top-performing AI trading bots.
Inhibrx Biosciences (INBX) Company Overview and Market Position
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company headquartered in La Jolla, California. The company develops novel biologic therapeutics using proprietary modular protein-engineering platforms designed to optimize the valency of antibody-based drug candidates. Its pipeline centers on two oncology programs: ozekibart (INBRX-109), a tetravalent DR5 agonist being studied in chondrosarcoma, Ewing sarcoma, colorectal cancer, and other solid tumors, and INBRX-106, a hexavalent OX40 agonist under investigation in non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
Inhibrx Biosciences was created in May 2024 through a spin-off from Inhibrx, Inc., which was simultaneously acquired by Sanofi in a transaction focused on the INBRX-101 alpha-1 antitrypsin program. As a pre-revenue, pre-commercial company, Inhibrx generates limited income from licenses and collaborations and relies on external financing to fund its clinical development. Investors follow the stock primarily for the binary value of its clinical readouts and the longer-term potential of its oncology pipeline.
Inhibrx Biosciences (INBX) Stock Price Performance: Last 30 Days vs. Quarter
Over the last 30 days, INBX has declined approximately 27%, falling from a closing price of $101.71 on September 28 to roughly $73.90 in late October. The move has been largely one-directional, with intermittent bounces that failed to hold and a series of lower highs and lower lows defining the near-term trend.
The broader quarterly picture is more nuanced. Measured against the roughly $84.73 level at the end of July, shares are down about 13% over the last three months. That relatively contained figure masks significant volatility: the stock spiked above $126 in late August before reversing lower through September and October. In short, the quarter featured a sharp rally followed by a near-complete retracement and further downside, leaving the stock well below its recent peak even as it remains well above its 52-week low.
What Drove INBX Stock Price in the Last 30 Days
The 30-day decline appears tied most directly to clinical data sentiment. In early September, Inhibrx reported data from its INBRX-106 program in head and neck squamous cell carcinoma, and the market's response was notably lukewarm. The stock sold off on unusually heavy volume around that release and continued to drift lower in the weeks that followed, reflecting investor skepticism about the data's competitive positioning in an increasingly crowded immuno-oncology landscape.
That catalyst was compounded by the stock's own positioning. After the late-August run-up, INBX carried elevated expectations and a large short interest base, making it vulnerable to profit-taking once the data narrative softened. As a pre-revenue clinical-stage company with a high-beta profile and significant cash burn, Inhibrx also remains sensitive to broader risk-off rotations in biotech and to any perceived setback in financing or development timelines.
What Drove INBX Stock Performance Over the Last Quarter
Over the last three months, INBX's performance has been defined by two opposing forces. In August, the stock staged a powerful rally that lifted shares from the low $80s to above $126, likely reflecting renewed optimism around its oncology pipeline and the momentum that often accompanies clinical-stage biotech names ahead of data. That enthusiasm, however, proved difficult to sustain. As September data from INBRX-106 drew a restrained reaction and broader sentiment cooled, the stock surrendered its August gains and moved below its pre-rally levels.
The quarter ultimately illustrates the two-sided risk inherent in single-asset and early-pipeline biotechs: outsized upside on favorable headlines, but equally sharp downside when data fails to exceed already-high expectations.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of AI-driven trading bots. While Tickeron offers hundreds of bots that trade thousands of tickers across different markets, only the top-performing and most relevant strategies appear in this featured section. The bots vary considerably in their approach, holding timeframe, and performance metrics, allowing users to compare strategies that fit different trading styles and risk tolerances. The page is designed to help traders quickly identify systems that are currently generating strong results, and it can serve as a useful starting point for those exploring systematic, data-driven approaches to the market.
INBX Stock Forecast Drivers: What Investors Should Watch Next
Several factors will shape INBX's trajectory going forward. First, Inhibrx's next earnings report, expected in mid-November, will offer updated commentary on cash runway, R&D spending, and development timelines. Second, additional data updates from INBRX-106 and ozekibart will be critical, given the market's demonstrated sensitivity to clinical readouts. Third, investors should monitor competitive developments across the OX40 and DR5 agonist spaces, where rival programs can shift the perceived value of Inhibrx's pipeline. Finally, financing remains a recurring theme for a pre-revenue company, so any equity offerings, debt arrangements, or partnership activity could influence both the balance sheet and the share count.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
INBX's MACD Histogram crosses above signal line
The Moving Average Convergence Divergence (MACD) for INBX turned positive on November 06, 2026. Looking at past instances where INBX's MACD turned positive, the stock continued to rise in 31 of 36 cases over the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INBX's RSI Oscillator exited the oversold zone, 30 of 36 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 54 of 69 cases where INBX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.
Following a +14.27% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in 224 of 287 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.
INBX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 10, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on INBX as a result. In 71 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 83%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 83%.
The Aroon Indicator for INBX entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 8 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-23.481) is normal, around the industry mean (3.498). P/E Ratio (-9.518) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (440.869).
The Tickeron PE Growth Rating for this company is 45 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a company, which engages in researching and developing biotechnology
Industry Biotechnology